Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about AGEN, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Balstilimab (AGEN2034) | Resectable MMR-deficient Solid Tumors | Phase 2/3 · NCT06279130 | Recruiting |
| Folfox Protocol | Gastric Cancer | Phase 3 · NCT06346197 | Recruiting |
| Irinotecan | Advanced Cancer | Phase 3 · NCT04943627 | Withdrawn |
| Botensilimab | Resectable MMR-deficient Solid Tumors | Phase 2/3 · NCT06279130 | Recruiting |
| XELOX | Gastric Cancer | Phase 3 · NCT06346197 | Recruiting |
| GVAX | Pancreatic Cancer | Phase 1/2 · NCT06782932 | Recruiting |
| QS21 | Herpes Simplex Type 2 | Phase 2 · NCT01687595 | Completed |
| Vitespen (HSPPC-96) | Recurrent Glioblastoma | Phase 2 · NCT01814813 | Terminated |
| Doxorubicin Hydrochloride | Newly Diagnosed Glioblastoma | Phase 2 · NCT05864534 | Active not recruiting |
| Pooled Mutant KRAS-Targeted Long Peptide | Pancreatic Cancer | Phase 1/2 · NCT06782932 | Recruiting |
| Zalifrelimab (AGEN1884) | Pancreatic Ductal Adenocarcinoma | Phase 1/2 · NCT04827953 | Active not recruiting |
| Nab-paclitaxel | Pancreatic Ductal Adenocarcinoma | Phase 1/2 · NCT04827953 | Active not recruiting |
| Hedgehog Inhibitor NLM-001 | Pancreatic Ductal Adenocarcinoma | Phase 1/2 · NCT04827953 | Active not recruiting |
| Anti-CD137 Agonistic Monoclonal Antibody | Pancreatic Cancer | Phase 1/2 · NCT06782932 | Recruiting |
| autologous human tumor-derived HSPPC-96 | Lymphoma, Follicular | Phase 2 · NCT00081809 | Completed |
| Balstilmab | Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1/2 · NCT05318469 | Recruiting |
Also used in these trials (approved or third-party drugs, not AGEN's own candidates): Leucovorin, Gemcitabine Hydrochloride, Nivolumab, Vinorelbine, Topotecan, Pemetrexed Disodium, Ipilimumab, Ivermectin, Oxaliplatin, Pembrolizumab, Panitumumab, GM-CSF-encoding Oncolytic Adenovirus CGTG-102.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
AGEN holds $18.7M in cash and short-term investments (as of Jun 30, 2026) and burns about $33.6M/quarter from operations, an estimated runway of 1.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 59 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AGEN files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Raymond Debbane | 5%+ holder (13G) | 4,533,755 | 10.07% | 2026-07-13 |
| RA Capital Management, L.P. | Institution (13G, 5%+) | 4,344,772 | 9.65% | 2026-07-13 |
| BlackRock, Inc. | Institution (13G, 5%+) | 2,513,893 | 5.58% | 2026-06-30 |
| ZYNEXT VENTURES USA LLC | 5%+ holder (13D) | 2,133,333 | 4.74% | 2026-01-15 |
| Garo H Armen Chairman, Chief Executive Officer and Pr · +2.11M options |
Insider | 400,058 | 0.89% | 2026-07-10 |
| Thomas L Harrison Director · +172,500 options |
Insider | 51,988 | 0.12% | 2026-10-01 |
| Austin Charette Principal Accounting Officer · +17,619 options |
Insider | 9,115 | 0.02% | 2026-01-08 |
| Marco Tullio Marcucci Director · +7,500 options |
Insider | 5,480 | 0.01% | 2026-08-05 |
Share count 45,020,407 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AGEN and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →